Key clinical point: Combination obinutuzumab and lenalidomide showed manageable safety and activity in patients with relapsed/refractory follicular lymphoma (FL).
Major finding: Basal cell carcinoma (6%), febrile neutropenia (5%), and infusion-related reactions (3%) were the most frequently reported serious toxicities, while the proportion of patients who achieved an overall response at induction end was 79%.
Study details: A phase 2 study of 89 patients with relapsed/refractory FL.
Disclosures: The Lymphoma Academic Research Organisation, Celgene, and Roche funded the study. The authors reported financial affiliations with the study sponsors and several other companies.
Morschhauser F et al. Lancet Haematol. 2019 Jul 8. doi: 10.1016/S2352-3026(19)30089-4.